Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTW66JKS)

• DOT Name: Centrosome-associated protein ALMS1 (ALMS1)
• Synonyms: Alstrom syndrome protein 1
• Gene Name: ALMS1
• Related Disease:
  Alstrom syndrome
  Acute myocardial infarction
  Bardet biedl syndrome
  Ciliopathy
  Classic Hodgkin lymphoma
  Cone-rod dystrophy
  Dilated cardiomyopathy
  Fatty liver disease
  Myocardial infarction
  Obesity
  Polydactyly
  Type-1/2 diabetes
  Chronic kidney disease
  High blood pressure
  Limb-girdle muscular dystrophy
  Retinopathy
  Hyperinsulinemia
  Blindness
  Cardiomyopathy
  Cone-rod dystrophy 2
  Dilated cardiomyopathy 1A
  Non-insulin dependent diabetes
  Schizophrenia
  Type-1 diabetes
• UniProt ID: ALMS1_HUMAN
• Pfam ID: PF15309 ; PF18727
• Sequence:
  MEPEDLPWPGELEEEEEEEEEEEEEEEEAAAAAAANVDDVVVVEEVEEEAGRELDSDSHY
  GPQHLESIDDEEDEEAKAWLQAHPGRILPPLSPPQHRYSEGERTSLEKIVPLTCHVWQQI
  VYQGNSRTQISDTNVVCLETTAQRGSGDDQKTESWHCLPQEMDSSQTLDTSQTRFNVRTE
  DTEVTDFPSLEEGILTQSENQVKEPNRDLFCSPLLVIQDSFASPDLPLLTCLTQDQEFAP
  DSLFHQSELSFAPLRGIPDKSEDTEWSSRPSEVSEALFQATAEVASDLASSRFSVSQHPL
  IGSTAVGSQCPFLPSEQGNNEETISSVDELKIPKDCDRYDDLCSYMSWKTRKDTQWPENN
  LADKDQVSVATSFDITDENIATKRSDHFDAARSYGQYWTQEDSSKQAETYLTKGLQGKVE
  SDVITLDGLNENAVVCSERVAELQRKPTRESEYHSSDLRMLRMSPDTVPKAPKHLKAGDT
  SKGGIAKVTQSNLKSGITTTPVDSDIGSHLSLSLEDLSQLAVSSPLETTTGQHTDTLNQK
  TLADTHLTEETLKVTAIPEPADQKTATPTVLSSSHSHRGKPSIFYQQGLPDSHLTEEALK
  VSAAPGLADQTTGMSTLTSTSYSHREKPGTFYQQELPESNLTEEPLEVSAAPGPVEQKTG
  IPTVSSTSHSHVEDLLFFYRQTLPDGHLTDQALKVSAVSGPADQKTGTATVLSTPHSHRE
  KPGIFYQQEFADSHQTEETLTKVSATPGPADQKTEIPAVQSSSYSQREKPSILYPQDLAD
  SHLPEEGLKVSAVAGPADQKTGLPTVPSSAYSHREKLLVFYQQALLDSHLPEEALKVSAV
  SGPADGKTGTPAVTSTSSASSSLGEKPSAFYQQTLPNSHLTEEALKVSIVPGPGDQKTGI
  PSAPSSFYSHREKPIIFSQQTLPDFLFPEEALKVSAVSVLAAQKTGTPTVSSNSHSHSEK
  SSVFYQQELPDSDLPRESLKMSAIPGLTDQKTVPTPTVPSGSFSHREKPSIFYQQEWPDS
  YATEKALKVSTGPGPADQKTEIPAVQSSSYPQREKPSVLYPQVLSDSHLPEESLKVSAFP
  GPADQMTDTPAVPSTFYSQREKPGIFYQQTLPESHLPKEALKISVAPGLADQKTGTPTVT
  STSYSQHREKPSIFHQQALPGTHIPEEAQKVSAVTGPGNQKTWIPRVLSTFYSQREKPGI
  FYQQTLPGSHIPEEAQKVSPVLGPADQKTGTPTPTSASYSHTEKPGIFYQQVLPDNHPTE
  EALKISVASEPVDQTTGTPAVTSTSYSQYREKPSIFYQQSLPSSHLTEEAKNVSAVPGPA
  DQKTVIPILPSTFYSHTEKPGVFYQQVLPHSHPTEEALKISVASEPVDQTTGTPTVTSTS
  YSQHTEKPSIFYQQSLPGSHLTEEAKNVSAVPGPGDRKTGIPTLPSTFYSHTEKPGSFYQ
  QVLPHSHLPEEALEVSVAPGPVDQTIGTPTVTSPSSSFGEKPIVIYKQAFPEGHLPEESL
  KVSVAPGPVGQTTGAPTITSPSYSQHRAKSGSFYQLALLGSQIPEEALRVSSAPGPADQT
  TGIPTITSTSYSFGEKPIVNYKQAFPDGHLPEEALKVSIVSGPTEKKTDIPAGPLGSSAL
  GEKPITFYRQALLDSPLNKEVVKVSAAPGPADQKTETLPVHSTSYSNRGKPVIFYQQTLS
  DSHLPEEALKVPPVPGPDAQKTETPSVSSSLYSYREKPIVFYQQALPDSELTQEALKVSA
  VPQPADQKTGLSTVTSSFYSHTEKPNISYQQELPDSHLTEEALKVSNVPGPADQKTGVST
  VTSTSYSHREKPIVSYQRELPHFTEAGLKILRVPGPADQKTGINILPSNSYPQREHSVIS
  YEQELPDLTEVTLKAIGVPGPADQKTGIQIASSSSYSNREKASIFHQQELPDVTEEALNV
  FVVPGQGDRKTEIPTVPLSYYSRREKPSVISQQELPDSHLTEEALKVSPVSIPAEQKTGI
  PIGLSSSYSHSHKEKLKISTVHIPDDQKTEFPAATLSSYSQIEKPKISTVIGPNDQKTPS
  QTAFHSSYSQTVKPNILFQQQLPDRDQSKGILKISAVPELTDVNTGKPVSLSSSYFHREK
  SNIFSPQELPGSHVTEDVLKVSTIPGPAGQKTVLPTALPSSFSHREKPDIFYQKDLPDRH
  LTEDALKISSALGQADQITGLQTVPSGTYSHGENHKLVSEHVQRLIDNLNSSDSSVSSNN
  VLLNSQADDRVVINKPESAGFRDVGSEEIQDAENSAKTLKEIRTLLMEAENMALKRCNFP
  APLARFRDISDISFIQSKKVVCFKEPSSTGVSNGDLLHRQPFTEESPSSRCIQKDIGTQT
  NLKCRRGIENWEFISSTTVRSPLQEAESKVSMALEETLRQYQAAKSVMRSEPEGCSGTIG
  NKIIIPMMTVIKSDSSSDASDGNGSCSWDSNLPESLESVSDVLLNFFPYVSPKTSITDSR
  EEEGVSESEDGGGSSVDSLAAHVKNLLQCESSLNHAKEILRNAEEEESRVRAHAWNMKFN
  LAHDCGYSISELNEDDRRKVEEIKAELFGHGRTTDLSKGLQSPRGMGCKPEAVCSHIIIE
  SHEKGCFRTLTSEHPQLDRHPCAFRSAGPSEMTRGRQNPSSCRAKHVNLSASLDQNNSHF
  KVWNSLQLKSHSPFQNFIPDEFKISKGLRMPFDEKMDPWLSELVEPAFVPPKEVDFHSSS
  QMPSPEPMKKFTTSITFSSHRHSKCISNSSVVKVGVTEGSQCTGASVGVFNSHFTEEQNP
  PRDLKQKTSSPSSFKMHSNSQDKEVTILAEGRRQSQKLPVDFERSFQEEKPLERSDFTGS
  HSEPSTRANCSNFKEIQISDNHTLISMGRPSSTLGVNRSSSRLGVKEKNVTITPDLPSCI
  FLEQRELFEQSKAPRADDHVRKHHSPSPQHQDYVAPDLPSCIFLEQRELFEQCKAPYVDH
  QMRENHSPLPQGQDSIASDLPSPISLEQCQSKAPGVDDQMNKHHFPLPQGQDCVVEKNNQ
  HKPKSHISNINVEAKFNTVVSQSAPNHCTLAASASTPPSNRKALSCVHITLCPKTSSKLD
  SGTLDERFHSLDAASKARMNSEFNFDLHTVSSRSLEPTSKLLTSKPVAQDQESLGFLGPK
  SSLDFQVVQPSLPDSNTITQDLKTIPSQNSQIVTSRQIQVNISDFEGHSNPEGTPVFADR
  LPEKMKTPLSAFSEKLSSDAVTQITTESPEKTLFSSEIFINAEDRGHEIIEPGNQKLRKA
  PVKFASSSSVQQVTFSRGTDGQPLLLPYKPSGSTKMYYVPQLRQIPPSPDSKSDTTVESS
  HSGSNDAIAPDFPAQVLGTRDDDLSATVNIKHKEGIYSKRVVTKASLPVGEKPLQNENAD
  ASVQVLITGDENLSDKKQQEIHSTRAVTEAAQAKEKESLQKDTADSSAAAAAEHSAQVGD
  PEMKNLPDTKAITQKEEIHRKKTVPEEAWPNNKESLQINIEESECHSEFENTTRSVFRSA
  KFYIHHPVHLPSDQDICHESLGKSVFMRHSWKDFFQHHPDKHREHMCLPLPYQNMDKTKT
  DYTRIKSLSINVNLGNKEVMDTTKSQVRDYPKHNGQISDPQRDQKVTPEQTTQHTVSLNE
  LWNKYRERQRQQRQPELGDRKELSLVDRLDRLAKILQNPITHSLQVSESTHDDSRGERSV
  KEWSGRQQQRNKLQKKKRFKSLEKSHKNTGELKKSKVLSHHRAGRSNQIKIEQIKFDKYI
  LSKQPGFNYISNTSSDCRPSEESELLTDTTTNILSGTTSTVESDILTQTDREVALHERSS
  SVSTIDTARLIQAFGHERVCLSPRRIKLYSSITNQQRRYLEKRSKHSKKVLNTGHPLVTS
  EHTRRRHIQVANHVISSDSISSSASSFLSSNSTFCNKQNVHMLNKGIQAGNLEIVNGAKK
  HTRDVGITFPTPSSSEAKLEENSDVTSWSEEKREEKMLFTGYPEDRKLKKNKKNSHEGVS
  WFVPVENVESRSKKENVPNTCGPGISWFEPITKTRPWREPLREQNCQGQHLDGRGYLAGP
  GREAGRDLLRPFVRATLQESLQFHRPDFISRSGERIKRLKLIVQERKLQSMLQTERDALF
  NIDRERQGHQNRMCPLPKRVFLAIQKNKPISKKEMIQRSKRIYEQLPEVQKKREEEKRKS
  EYKSYRLRAQLYKKRVTNQLLGRKVPWD
• Function: Involved in PCM1-dependent intracellular transport. Required, directly or indirectly, for the localization of NCAPD2 to the proximal ends of centrioles. Required for proper formation and/or maintenance of primary cilia (PC), microtubule-based structures that protrude from the surface of epithelial cells.
• Tissue Specificity: Expressed in all tissues tested including adipose and pancreas. Expressed by beta-cells of the islets in the pancreas (at protein level).
• Reactome Pathway:
  Loss of Nlp from mitotic centrosomes (R-HSA-380259)
  Recruitment of mitotic centrosome proteins and complexes (R-HSA-380270)
  Loss of proteins required for interphase microtubule organization from the centrosome (R-HSA-380284)
  Recruitment of NuMA to mitotic centrosomes (R-HSA-380320)
  Anchoring of the basal body to the plasma membrane (R-HSA-5620912)
  AURKA Activation by TPX2 (R-HSA-8854518)
  Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942)

Molecular Interaction Atlas (MIA) of This DOT

24 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Alstrom syndrome	DISFVX55	Definitive	Autosomal recessive	[1]
Acute myocardial infarction	DISE3HTG	Strong	Biomarker	[2]
Bardet biedl syndrome	DISTBNZW	Strong	Biomarker	[3]
Ciliopathy	DIS10G4I	Strong	Genetic Variation	[4]
Classic Hodgkin lymphoma	DISV1LU6	Strong	Genetic Variation	[5]
Cone-rod dystrophy	DISY9RWN	Strong	Genetic Variation	[6]
Dilated cardiomyopathy	DISX608J	Strong	Biomarker	[7]
Fatty liver disease	DIS485QZ	Strong	CausalMutation	[8]
Myocardial infarction	DIS655KI	Strong	Genetic Variation	[9]
Obesity	DIS47Y1K	Strong	Biomarker	[10]
Polydactyly	DIS25BMZ	Strong	Biomarker	[11]
Type-1/2 diabetes	DISIUHAP	Strong	Genetic Variation	[12]
Chronic kidney disease	DISW82R7	moderate	Genetic Variation	[13]
High blood pressure	DISY2OHH	moderate	Altered Expression	[13]
Limb-girdle muscular dystrophy	DISI9Y1Z	moderate	Genetic Variation	[14]
Retinopathy	DISB4B0F	moderate	Biomarker	[14]
Hyperinsulinemia	DISIDWT6	Disputed	Biomarker	[15]
Blindness	DISTIM10	Limited	Genetic Variation	[16]
Cardiomyopathy	DISUPZRG	Limited	Genetic Variation	[17]
Cone-rod dystrophy 2	DISX2RWY	Limited	Genetic Variation	[6]
Dilated cardiomyopathy 1A	DIS0RK9Z	Limited	Biomarker	[7]
Non-insulin dependent diabetes	DISK1O5Z	Limited	Biomarker	[10]
Schizophrenia	DISSRV2N	Limited	Genetic Variation	[18]
Type-1 diabetes	DIS7HLUB	Limited	Genetic Variation	[19]

16 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[20]
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[21]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[22]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[23]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[24]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[25]
Quercetin	DM3NC4M	Approved	Quercetin decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[26]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide affects the expression of Centrosome-associated protein ALMS1 (ALMS1).	[27]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[28]
Phenobarbital	DMXZOCG	Approved	Phenobarbital decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[29]
Demecolcine	DMCZQGK	Approved	Demecolcine decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[30]
Tamibarotene	DM3G74J	Phase 3	Tamibarotene decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[22]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[32]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[33]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[35]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde increases the expression of Centrosome-associated protein ALMS1 (ALMS1).	[30]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Camptothecin	DM6CHNJ	Phase 3	Camptothecin decreases the methylation of Centrosome-associated protein ALMS1 (ALMS1).	[31]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 affects the phosphorylation of Centrosome-associated protein ALMS1 (ALMS1).	[34]

References

• [1] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [2] Genes associated with inflammation and the cell cycle may serve as biomarkers for the diagnosis and prognosis of acute myocardial infarction in a Chinese population.Mol Med Rep. 2018 Aug;18(2):1311-1322. doi: 10.3892/mmr.2018.9077. Epub 2018 May 25.
• [3] Functional analysis by minigene assay of putative splicing variants found in Bardet-Biedl syndrome patients.J Cell Mol Med. 2017 Oct;21(10):2268-2275. doi: 10.1111/jcmm.13147. Epub 2017 May 13.
• [4] Phenotypic and mutational spectrum of 21 Chinese patients with Alstrm syndrome.Am J Med Genet A. 2020 Feb;182(2):279-288. doi: 10.1002/ajmg.a.61412. Epub 2019 Nov 22.
• [5] Characterization of Alstrom Syndrome 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells.PLoS One. 2017 Jan 30;12(1):e0170694. doi: 10.1371/journal.pone.0170694. eCollection 2017.
• [6] Late diagnosis of Alstrom syndrome in a Yemenite-Jewish child.Ophthalmic Genet. 2019 Feb;40(1):7-11. doi: 10.1080/13816810.2018.1561900. Epub 2019 Jan 2.
• [7] Extreme clinical variability of dilated cardiomyopathy in two siblings with Alstrm syndrome.Pediatr Cardiol. 2013 Feb;34(2):455-8. doi: 10.1007/s00246-012-0296-6. Epub 2012 Mar 24.
• [8] A Next Generation Sequencing custom gene panel as first line diagnostic tool for atypical cases of syndromic obesity: Application in a case of Alstrm syndrome.Eur J Med Genet. 2018 Feb;61(2):79-83. doi: 10.1016/j.ejmg.2017.10.016. Epub 2017 Oct 24.
• [9] Identification of a glutamic acid repeat polymorphism of ALMS1 as a novel genetic risk marker for early-onset myocardial infarction by genome-wide linkage analysis.Circ Cardiovasc Genet. 2013 Dec;6(6):569-78. doi: 10.1161/CIRCGENETICS.111.000027. Epub 2013 Oct 11.
• [10] ALMS1 and Alstrm syndrome: a recessive form of metabolic, neurosensory and cardiac deficits.J Mol Med (Berl). 2019 Jan;97(1):1-17. doi: 10.1007/s00109-018-1714-x. Epub 2018 Nov 12.
• [11] Mutation spectrum in BBS genes guided by homozygosity mapping in an Indian cohort.Clin Genet. 2015 Feb;87(2):161-6. doi: 10.1111/cge.12342. Epub 2014 Feb 18.
• [12] Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.Obesity (Silver Spring). 2017 Jan;25(1):155-165. doi: 10.1002/oby.21701. Epub 2016 Nov 2.
• [13] Role of Alstrm syndrome 1 in the regulation of blood pressure and renal function.JCI Insight. 2018 Nov 2;3(21):e95076. doi: 10.1172/jci.insight.95076.
• [14] Nonsyndromic Early-Onset Cone-Rod Dystrophy and Limb-Girdle Muscular Dystrophy in a Consanguineous Israeli Family are Caused by Two Independent yet Linked Mutations in ALMS1 and DYSF.Hum Mutat. 2015 Sep;36(9):836-41. doi: 10.1002/humu.22822. Epub 2015 Jul 14.
• [15] Genomic knockout of alms1 in zebrafish recapitulates Alstrm syndrome and provides insight into metabolic phenotypes.Hum Mol Genet. 2019 Jul 1;28(13):2212-2223. doi: 10.1093/hmg/ddz053.
• [16] Alstrm Syndrome: Mutation Spectrum of ALMS1.Hum Mutat. 2015 Jul;36(7):660-8. doi: 10.1002/humu.22796. Epub 2015 May 18.
• [17] Homozygous loss-of-function mutation in ALMS1 causes the lethal disorder mitogenic cardiomyopathy in two siblings.Eur J Med Genet. 2014 Sep;57(9):532-5. doi: 10.1016/j.ejmg.2014.06.004. Epub 2014 Jun 24.
• [18] Genome-wide association study of schizophrenia in Ashkenazi Jews.Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):649-59. doi: 10.1002/ajmg.b.32349. Epub 2015 Jul 21.
• [19] A novel ALMS1 splice mutation in a non-obese juvenile-onset insulin-dependent syndromic diabetic patient.Eur J Hum Genet. 2014 Jan;22(1):140-3. doi: 10.1038/ejhg.2013.87. Epub 2013 May 8.
• [20] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [21] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [22] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [25] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [26] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [27] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [28] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [29] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [30] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [31] Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes. Environ Toxicol. 2019 Apr;34(4):401-414.
• [32] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [33] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [34] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [35] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.